Claims for harm from Allergan implants in Pennsylvania

Pennsylvania plaintiffs may join MDL 2921 in the District of New Jersey (Judge Brian R. Martinotti) — Pennsylvania's geographic proximity to Newark makes this forum particularly accessible. Pennsylvania state court does not have a statewide BIOCELL coordinated proceeding; however, Philadelphia County Court of Common Pleas (Complex Litigation Center, Mass Tort Program) is an established and well-developed mass tort venue that handles asbestos, pharmaceutical, and medical device cases and could receive coordinated BIOCELL filings.

Pennsylvania's personal injury statute of limitations is two years under 42 Pa. C.S. § 5524(2). Pennsylvania recognizes the discovery rule for latent disease: the clock runs from the point at which the plaintiff knew or, exercising reasonable diligence, should have known of the injury and its cause. The Pennsylvania Supreme Court applies this standard in a plaintiff-favorable manner for occupational disease and medical device cases. For BIA-ALCL plaintiffs, the diagnosis date is the standard discovery-rule anchor.

Philadelphia's Mass Tort Program, administered by the Complex Litigation Center, is one of the most active in the nation and has managed Roundup, opioid, and hernia mesh mass torts. BIOCELL filings could be coordinated there before a designated Mass Tort judge. In federal court, the Eastern District of Pennsylvania (Philadelphia) handles pre-transfer proceedings; judges there (e.g., Judge Mitchell Goldberg) are familiar with complex MDL protocols. The Middle and Western Districts (Harrisburg, Pittsburgh) are less common BIOCELL venues.

Pennsylvania BIOCELL exposure is concentrated in the Philadelphia metropolitan area (including Delaware County, Montgomery County, and Chester County), Pittsburgh (Allegheny County), and suburban communities near major academic plastic surgery programs at Penn Medicine, Jefferson Health, Temple University Hospital, and UPMC. Pennsylvania's dense network of academic and community plastic surgery practices placed substantial volumes of BIOCELL implants during the 2005–2019 period, and proximity to the MDL venue in Newark makes Pennsylvania plaintiffs natural MDL candidates.